|
gptkbp:instanceOf
|
gptkb:biotechnology
gptkb:state-owned_enterprise
|
|
gptkbp:abbreviation
|
gptkb:China_National_Pharmaceutical_Group_Corporation
|
|
gptkbp:country
|
gptkb:China
|
|
gptkbp:founded
|
1998
|
|
gptkbp:headquarters_location
|
gptkb:Beijing
|
|
gptkbp:industry
|
healthcare
pharmaceuticals
|
|
gptkbp:listedOn
|
gptkb:Fortune_Global_500
|
|
gptkbp:notableProduct
|
gptkb:Sinopharm_BIBP_COVID-19_vaccine
gptkb:Sinopharm_WIBP_COVID-19_vaccine
|
|
gptkbp:numberOfEmployees
|
over 100,000
|
|
gptkbp:parentOrganization
|
gptkb:State-owned_Assets_Supervision_and_Administration_Commission_of_the_State_Council
|
|
gptkbp:product
|
pharmaceuticals
medical equipment
vaccines
|
|
gptkbp:revenue
|
over 70 billion USD (2022)
|
|
gptkbp:stockExchange
|
gptkb:Hong_Kong_Stock_Exchange
|
|
gptkbp:subsidiary
|
gptkb:China_National_Pharmaceutical_Group
|
|
gptkbp:website
|
http://www.sinopharm.com/
|
|
gptkbp:bfsParent
|
gptkb:COVAX
gptkb:China_National_Pharmaceutical_Group
gptkb:Sinopharm_Group
gptkb:Gavi,_the_Vaccine_Alliance
gptkb:Sinopharm_BIBP_COVID-19_vaccine
gptkb:COVID-19_pandemic_(2020)
|
|
gptkbp:bfsLayer
|
6
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Sinopharm
|